This Article Full Text Free Full Text (PDF) Free All Versions of this Article: chest.07-0149v1 132/2/447    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dimopoulos, G. Articles by Falagas, M. E. Search for Related Content PubMed PubMed Citation Articles by Dimopoulos, G. Articles by Falagas, M. E.

Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis^*

A Metaanalysis of Randomized Controlled Trials

^* From the Critical Care Department (Dr. Dimopoulos), "Attikon" University Hospital, Athens, Greece; and Alfa Institute of Biomedical Sciences (Drs. Siempos, Korbila, Manta, and Falagas), Athens, Greece.

Correspondence to: Matthew E. Falagas, MD, MSc, DSc, Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos St, 151 23 Marousi, Greece; e-mail: m.falagas{at}aibs.gr

Abstract

Background: Although acute exacerbations of chronic bronchitis (AECBs) are common, there has been no metaanalysis that focused on the optimum regimen.

Methods: To evaluate the comparative effectiveness and safety of first-line antimicrobial agents (ie, amoxicillin, ampicillin, pivampicillin, trimethoprim/sulfamethoxazole, and doxycycline) and second-line antimicrobial agents (ie, amoxicillin/clavulanic acid, macrolides, second-generation or third-generation cephalosporins, and quinolones) for the treatment of patients with AECB, in an era of increasing antimicrobial resistance among the microbes responsible for AECB, we performed a metaanalysis of randomized controlled trials (RCTs) retrieved through searches of the PubMed and the Cochrane databases.

Results: Twelve RCTs were included in the metaanalysis. First-line antibiotics were associated with lower treatment success compared to second-line antibiotics in the clinically evaluable patients (odds ratio [OR], 0.51; 95% confidence interval [CI], 0.34 to 0.75). There were no differences among the compared regimens regarding mortality (OR, 0.64; 95% CI, 0.25 to 1.66) or treatment success (OR, 0.56; 95% CI, 0.22 to 1.43) in microbiologically evaluable patients, or adverse effects in general (OR, 0.75; 95% CI, 0.39 to 1.45) or diarrhea in particular (OR, 1.58; 95% CI, 0.74 to 3.35).

Conclusions: Compared to first-line antibiotics, second-line antibiotics are more effective, but not less safe, when administered to patients with AECB. The available data did not allow for stratified analyses according to the presence of risk factors for poor outcome, such as increased age, impaired lung function, airway obstruction, and frequency of exacerbations; this fact should be taken into consideration when interpreting the findings of this metaanalysis.

Key Words: amoxicillin/clavulanic acid • COPD • macrolides • penicillins • quinolones • Streptococcus pneumoniae

This article has been cited by other articles:

				P. Laohaburanakit, G. Dimopoulos, I. I. Siempos, M. E. Falagas, and R. Irwin Antibiotic Use in Acute Exacerbations of Chronic Bronchitis Chest, December 1, 2007; 132(6): 2063 - 2064. [Full Text] [PDF]